NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”